Axaron Bioscience AG Report issue

For profit Phase 2
Founded: Heidelberg Germany (1997)
Status: Acquired by Sygnis Bioscience GmbH & Co KG (2006) → now Expedeon (2017)

Organization Overview

First Clinical Trial
2004
NCT00132470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1